Emma Ingleson
University of Leeds(GB)Cancer Research UK Clinical Trials Unit(GB)
Publications by Year
Research Areas
Health Policy Implementation Science, Multiple Myeloma Research and Treatments, Primary Care and Health Outcomes, Mental Health and Patient Involvement, Protein Degradation and Inhibitors
Most-Cited Works
- → Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma(2023)104 cited
- → Using the Theoretical Domains Framework (TDF) to understand adherence to multiple evidence-based indicators in primary care: a qualitative study(2015)97 cited
- → To what extent can behaviour change techniques be identified within an adaptable implementation package for primary care? A prospective directed content analysis(2018)36 cited
- → Acute and Late Adverse Events Associated With Radical Radiation Therapy Prostate Cancer Treatment: A Systematic Review of Clinician and Patient Toxicity Reporting in Randomized Controlled Trials(2016)34 cited
- → A Needs-led Framework for Understanding the Impact of Caring for a Family Member With Dementia(2017)31 cited
- → Development of an Item Pool for a Needs-Based Measure of Quality of Life of Carers of a Family Member with Dementia(2018)19 cited
- → Action to Support Practices Implement Research Evidence (ASPIRE): protocol for a cluster-randomised evaluation of adaptable implementation packages targeting ‘high impact’ clinical practice recommendations in general practice(2015)19 cited
- → Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.(2021)17 cited
- → Developing and evaluating packages to support implementation of quality indicators in general practice: the ASPIRE research programme, including two cluster RCTs(2020)16 cited
- → Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial(2022)10 cited